We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+6.15%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.05B
AUM Growth
-$412M
(-17%)
Cap. Flow
-$506M
Cap. Flow
% of AUM
-24.65%
Top 10 Holdings %
Top 10 Hldgs %
62.87%
Holding
41
New
10
Increased
7
Reduced
9
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenet Healthcare
THC
|
+$69.8M |
| 2 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$33.7M |
| 3 |
Biogen
BIIB
|
+$26.4M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$23.3M |
| 5 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$21.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LivaNova
LIVN
|
+$58.8M |
| 2 |
Perrigo
PRGO
|
+$53.7M |
| 3 |
CSII
Cardiovascular Systems, Inc.
CSII
|
+$49.5M |
| 4 |
Abbott
ABT
|
+$44.4M |
| 5 |
Alkermes
ALKS
|
+$42.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVTA
26
DELISTED
Invitae Corporation
NVTA
| $22.9M | 1.12% |
2,398,123
| – | – |
|
|
EVHC
27
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $21.9M | 1.07% |
+350,000
| New | +$20.2M |
|
|
AVXS
28
DELISTED
AveXis, Inc. Common Stock
AVXS
| $17.3M | 0.84% |
+210,000
| New | +$15.7M |
|
|
RAD
29
DELISTED
Rite Aid Corporation
RAD
| $14.8M | 0.72% |
+250,000
| New | +$18.9M |
|
30
PTC Therapeutics
PTCT
$6.26B
| $9.16M | 0.45% |
500,000
-750,000
| -60% | -$10.1M |
|
31
Atara Biotherapeutics
ATRA
$73.6M
| $7.5M | 0.37% |
21,420
+16,420
| +328% | +$6.33M |
|
|
ARNA
32
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $7.17M | 0.35% |
425,000
| – | – |
|
|
BIOL
33
DELISTED
Biolase, Inc.
BIOL
| $5.17M | 0.25% |
427
| – | – |
|
|
RDUS
34
DELISTED
Radius Health, Inc.
RDUS
| $4.52M | 0.22% |
+100,000
| New | +$3.82M |
|
|
35
Abbott
ABT
$183B
| – | – |
-1,000,000
| Closed | -$44.4M |
|
|
36
Alkermes
ALKS
$8.39B
| – | – |
-725,000
| Closed | -$42.4M |
|
|
37
LivaNova
LIVN
$4.45B
| – | – |
-1,200,000
| Closed | -$58.8M |
|
38
Puma Biotechnology
PBYI
$402M
| – | – |
-650,000
| Closed | -$24.2M |
|
|
39
Perrigo
PRGO
$1.43B
| – | – |
-808,200
| Closed | -$53.7M |
|
|
CSII
40
DELISTED
Cardiovascular Systems, Inc.
CSII
| – | – |
-1,750,000
| Closed | -$49.5M |
|
|
DXTR
41
DELISTED
Dextera Surgical Inc.
DXTR
| – | – |
-837,483
| Closed | -$888K |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2017 Portfolio in Review
As of Q2 2017, Camber Capital Management held 41 positions worth $2.05B, down 17% from $2.47B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Camber Capital Management withdrew a net $506M in Q2 2017, closing 7 positions and reducing 9 holdings. Its most notable exit was LivaNova, an estimated $58.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 60% a quarter earlier.
Against the trend, Camber Capital Management opened a new position in Tenet Healthcare worth $77.4M.
- Camber Capital Management's largest Q2 2017 buy was Tenet Healthcare: 4,000,000 shares worth $77.4M.
- Camber Capital Management added most to Endologix Inc in Q2 2017, an estimated $8.83M increase.
- Camber Capital Management's biggest Q2 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $36.1M.
- Camber Capital Management fully exited LivaNova in Q2 2017, selling an estimated $58.8M.
- Camber Capital Management's ten largest holdings make up 63% of its $2.05B portfolio in Q2 2017.
- Camber Capital Management opened 10 new positions and closed 7 in Q2 2017.
- Camber Capital Management's portfolio value fell 17% quarter-over-quarter to $2.05B.
Based on Camber Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.